Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer

OBJECTIVE: Despite advances in cervical cancer prevention and diagnosis, outcomes for patients given a diagnosis of advanced and recurrent disease are poor. In the GOG240 trial, the addition of bevacizumab to paclitaxel-topotecan or paclitaxel-cisplatin has been shown to prolong survival compared wi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Gynecol Cancer
Autors principals: Rosen, Virginia M., Guerra, Ines, McCormack, Mary, Nogueira-Rodrigues, Angélica, Sasse, Andre, Munk, Veronica C., Shang, Aijing
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2017
Matèries:
Cervical Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5499964/
https://ncbi.nlm.nih.gov/pubmed/28448304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IGC.0000000000001000
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars